Anti-MAGE-A3/HLA-A*0101 TCR T-cell therapy (Adaptimmune)

N/A

Report date: 2022/03/03 17:33:58

Base Information

Drug NameAnti-MAGE-A3/HLA-A*0101 TCR T-cell therapy (Adaptimmune)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMelanoma-associated antigen 3 modulators
TargetsMelanoma-associated antigen 3
Therapy Area/IndicationsOvarian NeoplasmsMultiple MyelomaMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAdaptimmune Llc
Active IndicationsN/A
Inactive IndicationsOvarian NeoplasmsMultiple MyelomaMelanoma

Other Information

ATC CodeN/A
Related LinksN/A